A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy
Abstract Background Women with endometrial or ovarian cancer experience a variety of symptoms during chemotherapy. Patient-Reported outcomes (PROs) can provide insight into the symptoms they experience. A PRO tool tailored to this patient population can help accurately monitor adverse events and man...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2023-07-01
|
| Series: | Journal of Patient-Reported Outcomes |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s41687-023-00611-w |
| _version_ | 1827895128134516736 |
|---|---|
| author | Mille Guldager Christiansen Helle Pappot Pernille Tine Jensen Mansoor Raza Mirza Mary Jarden Karin Piil |
| author_facet | Mille Guldager Christiansen Helle Pappot Pernille Tine Jensen Mansoor Raza Mirza Mary Jarden Karin Piil |
| author_sort | Mille Guldager Christiansen |
| collection | DOAJ |
| description | Abstract Background Women with endometrial or ovarian cancer experience a variety of symptoms during chemotherapy. Patient-Reported outcomes (PROs) can provide insight into the symptoms they experience. A PRO tool tailored to this patient population can help accurately monitor adverse events and manage symptoms. The objective of this study was to identify items in the National Cancer Institute’s measurement system Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) appropriate for use in a PRO tool for a population of women with endometrial or ovarian cancer undergoing treatment with taxanes (paclitaxel or docetaxel) in combination with carboplatin. Methods A two-phase, sequential multi-methods approach was applied. In phase one, a comprehensive literature search was done to map the toxicity of the applied chemotherapeutics and phase III clinical studies. Phase two, which comprised selecting the PRO-CTCAE items, included discussions with and feedback from a patient advisory board, an additional literature search, and focus group interviews with senior oncologists and specialized oncology nurses. A national expert panel facilitated both phases in terms of carefully select items from the PRO-CTCAE library. Results Phase one identified 18 symptoms and phase two, three additional ones, leading to the inclusion of 21 PRO-CTCAE symptoms in the final PRO tool. Since PRO-CTCAE also contains one to three sub-questions on the frequency, severity, and interference with daily activities of symptoms, there were 44 potential items. Conclusions This study describes taking a multi-method approach to selecting items from the PRO-CTCAE library for use in a population of women with endometrial or ovarian cancer undergoing chemotherapy. By systematically combining diverse approaches, we carefully selected 21 clinically relevant symptoms covered by 44 items in the PRO-CTCAE library. Future studies should investigate the psychometric properties of this PRO tool for women with endometrial or ovarian cancer. |
| first_indexed | 2024-03-12T22:17:04Z |
| format | Article |
| id | doaj.art-9e5e3371d1064a6193fc99135d7e8cd8 |
| institution | Directory Open Access Journal |
| issn | 2509-8020 |
| language | English |
| last_indexed | 2024-03-12T22:17:04Z |
| publishDate | 2023-07-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Journal of Patient-Reported Outcomes |
| spelling | doaj.art-9e5e3371d1064a6193fc99135d7e8cd82023-07-23T11:15:59ZengSpringerOpenJournal of Patient-Reported Outcomes2509-80202023-07-017111310.1186/s41687-023-00611-wA multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapyMille Guldager Christiansen0Helle Pappot1Pernille Tine Jensen2Mansoor Raza Mirza3Mary Jarden4Karin Piil5Department of Oncology, Centre for Cancer and Organ Diseases, Copenhagen University HospitalDepartment of Oncology, Centre for Cancer and Organ Diseases, Copenhagen University HospitalDepartment of Gynecology and Obstetrics, Aarhus University HospitalDepartment of Oncology, Centre for Cancer and Organ Diseases, Copenhagen University HospitalDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of CopenhagenDepartment of Oncology, Centre for Cancer and Organ Diseases, Copenhagen University HospitalAbstract Background Women with endometrial or ovarian cancer experience a variety of symptoms during chemotherapy. Patient-Reported outcomes (PROs) can provide insight into the symptoms they experience. A PRO tool tailored to this patient population can help accurately monitor adverse events and manage symptoms. The objective of this study was to identify items in the National Cancer Institute’s measurement system Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®) appropriate for use in a PRO tool for a population of women with endometrial or ovarian cancer undergoing treatment with taxanes (paclitaxel or docetaxel) in combination with carboplatin. Methods A two-phase, sequential multi-methods approach was applied. In phase one, a comprehensive literature search was done to map the toxicity of the applied chemotherapeutics and phase III clinical studies. Phase two, which comprised selecting the PRO-CTCAE items, included discussions with and feedback from a patient advisory board, an additional literature search, and focus group interviews with senior oncologists and specialized oncology nurses. A national expert panel facilitated both phases in terms of carefully select items from the PRO-CTCAE library. Results Phase one identified 18 symptoms and phase two, three additional ones, leading to the inclusion of 21 PRO-CTCAE symptoms in the final PRO tool. Since PRO-CTCAE also contains one to three sub-questions on the frequency, severity, and interference with daily activities of symptoms, there were 44 potential items. Conclusions This study describes taking a multi-method approach to selecting items from the PRO-CTCAE library for use in a population of women with endometrial or ovarian cancer undergoing chemotherapy. By systematically combining diverse approaches, we carefully selected 21 clinically relevant symptoms covered by 44 items in the PRO-CTCAE library. Future studies should investigate the psychometric properties of this PRO tool for women with endometrial or ovarian cancer.https://doi.org/10.1186/s41687-023-00611-wItem selectionPatient-reported outcomesPROOvarian cancerEndometrial cancerPRO-CTCAE library |
| spellingShingle | Mille Guldager Christiansen Helle Pappot Pernille Tine Jensen Mansoor Raza Mirza Mary Jarden Karin Piil A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy Journal of Patient-Reported Outcomes Item selection Patient-reported outcomes PRO Ovarian cancer Endometrial cancer PRO-CTCAE library |
| title | A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy |
| title_full | A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy |
| title_fullStr | A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy |
| title_full_unstemmed | A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy |
| title_short | A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy |
| title_sort | multi method approach to selecting pro ctcae symptoms for patient reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy |
| topic | Item selection Patient-reported outcomes PRO Ovarian cancer Endometrial cancer PRO-CTCAE library |
| url | https://doi.org/10.1186/s41687-023-00611-w |
| work_keys_str_mv | AT milleguldagerchristiansen amultimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy AT hellepappot amultimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy AT pernilletinejensen amultimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy AT mansoorrazamirza amultimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy AT maryjarden amultimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy AT karinpiil amultimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy AT milleguldagerchristiansen multimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy AT hellepappot multimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy AT pernilletinejensen multimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy AT mansoorrazamirza multimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy AT maryjarden multimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy AT karinpiil multimethodapproachtoselectingproctcaesymptomsforpatientreportedoutcomeinwomenwithendometrialorovariancancerundergoingchemotherapy |